Premium
Topical Cidofovir for Recalcitrant Verrucae in Individuals with Severe Combined Immunodeficiency After Hematopoietic Stem Cell Transplantation
Author(s) -
Henrickson Sarah E.,
Treat James R.
Publication year - 2016
Publication title -
pediatric dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 73
eISSN - 1525-1470
pISSN - 0736-8046
DOI - 10.1111/pde.12992
Subject(s) - cidofovir , medicine , hematopoietic stem cell transplantation , severe combined immunodeficiency , imiquimod , transplantation , immunodeficiency , dermatology , stem cell , surgery , immunology , immune system , biochemistry , virus , chemistry , genetics , biology , gene
Verrucae vulgaris in patients with severe combined immunodeficiency ( SCID ) after hematopoietic stem cell transplantation ( HCST ) can be challenging to manage. We describe two brothers with X‐linked SCID who had severe, persistent verrucae that did not respond to traditional topical therapies, including liquid nitrogen, imiquimod, salicylic acid, sinecatechins, 40% urea, and 5‐fluorourcil. Both brothers had full response to topical 3% cidofovir, which should be considered in recalcitrant warts in individuals with SCID after HSCT .